News Pathos AI signs two cancer deals with Alphamab and AZ Pathos AI has grown its oncology pipeline by licensing a bispecific ADC from Alphamab for $125m and partnering a breast cancer drug from AstraZeneca.
News Pathos AI's big $365m Series D, and other bio financings Our round-up of recent biotech financings includes rounds for Pathos AI, Stylus Medicine, Haya Therapeutics, Therini Bio and Tiltbio.
News AstraZeneca joins Tempus, Pathos in cancer AI project AstraZeneca has started work with Tempus and Pathos AI on a $200m project to build a comprehensive multimodal foundation model for oncology.
News TransThera's resistant biliary cancer drug cleared in China TransThera's Yochanra has been cleared in China as the world's first drug that can overcome resistance to FGFR inhibitors in cholangiocarcinoma.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.